ArticleCell death discovery2026
Deubiquitinase USP35 regulates MDM4 degradation to promote endothelial ferroptosis and renal injury progression.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systematic characterization of pyroptosis-related gene patterns identifies potential prognostic inflammatory phenotypes in sepsis.Functional & integrative genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin is a widely used chemotherapeutic drug for various types of malignant tumors, but its nephrotoxic side effects limit its clinical application. There have been numerous reports and studies on cisplatin-induced acute kidney injury (AKI). Through transcriptomic and single-cell analyses, we found that USP35 is highly expressed in AKI and is closely related to MDM4. We investigated the role and mechanism of USP35-mediated MDM4 ubiquitination in AKI using renal epithelial cells and animal models. In a kidney-specific USP35 knockout model, AKI was significantly improved, and endothelial ferroptosis was inhibited. Overexpression of USP35 can promote AKI and endothelial ferroptosis. USP35 induces the autophagic degradation of MDM4 following deubiquitination, which activates the P53 signaling pathway mediating endothelial ferroptosis. We propose that the USP35-MDM4-P53 signaling pathway plays an important role in AKI and indicates that USP35 is a potential therapeutic target for AKI.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.